Novartis' Gilenya staves off generic challengers—for now—after federal injunction | Fierce Pharma
Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court | Fierce Pharma
Novartis (NOVN) Wins U.S. Appeal Affirming Patent on MS Drug - Bloomberg
Alembic Pharma: How to win the US: Alembic Pharma will have to crack the complex-products game - The Economic Times
/cloudfront-us-east-2.images.arcpublishing.com/reuters/52AGE63A7FL7ZKCF7MWDNTV7QQ.jpg "U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug | Reuters")
U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug | Reuters
Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic) - Not-so-Hidden Gems - ValuePickr Forum
Novartis dodges Gilenya kickback claims—again
Stampeding generics expected to trample Lilly's now-off-patent ADHD med Strattera | Fierce Pharma
/cloudfront-us-east-2.images.arcpublishing.com/reuters/S2ZVV3DI4ZIZHAUZZLLFYCSR6Y.jpg "U.S. Supreme Court grants Novartis request to halt Gilenya generic rivals | Reuters")
U.S. Supreme Court grants Novartis request to halt Gilenya generic rivals | Reuters
Alembic Pharma gets USFDA approval for hypertension drug - Elets eHealth
FiercePharmaAsia—Takeda's workforce rejig and Velcade patent win, China's insurance drug list | Fierce Pharma
The top 10 generic drug makers by 2021 revenue
FDA greenlights generics of Novartis' $3B MS star Gilenya amid legal fight | Fierce Pharma
natco: Patent infringement lawsuit filed against Natco by Johnson & Johnson, Momenta - The Economic Times
Biogen Suffers Yet Another Setback as an Appeal for the Tecfidera Patent is Denied. | News & Updates
Novartis could snag a blockbuster MS market all for itself, just in time to fight Gilenya generics | Fierce Pharma
Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS - Bloomberg
Biogen takes another blow as appeal for Tecfidera patent revival falls short | Fierce Pharma
After win at patent office, Bristol Myers inks Revlimid deal with Dr. Reddy's | Fierce Pharma
Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS - Bloomberg
Aurobindo Pharma, Dr Reddys, Torrent Pharma, Mylan cannot sell generic Gilenya patented by Novartis
Gilead's $3B Truvada will face generics a year early. Can Descovy still win over its patients? | Fierce Pharma
Novartis wins Supreme Court temporary reprieve on Gilenya generics (NYSE:NVS) | Seeking Alpha
Novartis loses appeal for patent on multiple sclerosis drug (NYSE:NVS) | Seeking Alpha
Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma
Riding on patent office win, Novartis takes Gilenya generics fight to court | Fierce Pharma
/cloudfront-us-east-2.images.arcpublishing.com/reuters/4SADGYNDOJLEBHXQYSBDSEA5AI.jpg "Novartis loses in patent appeal over multiple sclerosis drug | Reuters")